RecruitingNot Applicable

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

United States40 participantsStarted 2025-06-27

Plain-language summary

The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs (SSPs) to implement routine, opt-out HIV and Hepatitis C (HCV) testing and linkage to care for people who inject drugs (PWID).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. be operating in an Ending the HIV Epidemic (EHE) or Centers for Disease Control and Prevention (CDC) determined vulnerable jurisdictions;
✓. serve at least 300 unique participants per year;
✓. not currently offer opt-out HIV/HCV testing;
✓. be capable and willing to prospectively collect aggregated, site-level data on the number of participants who are: i) offered HIV/HCV screening, ii) completed these tests, and iii) linked to care, as well as provide participant demographics;
✓. have key staff that consent to participate in study surveys, qualitative interviews and practice facilitation throughout the study.

Exclusion criteria

✕. currently receive or have received Frontline Communities in the United States (FOCUS) funding;
✕. have already implemented opt-out HIV/HCV testing.
✕. currently participating in SAIA-SSP-HIV (NCT06025435)

What they're measuring

Number of SSP participants reached

Timeframe: up to 18 months

Adoption

Timeframe: up to 6 months

Trial details

NCT IDNCT06730555

SponsorUniversity of Miami

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-08-01

Contact for this trial

Hansel Tookes, MD

3056897030 hetookes@miami.edu

View on ClinicalTrials.gov More HIV Infections trials